The Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial established that, for patients with stable coronary artery disease (CAD), an initial management strategy of percutaneous coronary intervention plus optimal medical therapy did not reduce the long-term rates of death, myocardial infarction, or other cardiovascular events as compared with optimal medical therapy alone. The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial reported that for patients with type 2 diabetes and stable CAD, a strategy of prompt coronary revascularization and intensive medical therapy did not reduce all-cause mortality or the composite of death, myocardial infarction or stroke compared with intensive medical therapy alone; however, in the group of patients appropriate for coronary artery bypass graft surgery (CABG), prompt revascularization with CABG resulted in significantly lower rates of major cardiovascular events, specifically myocardial infarction, than intensive medical therapy alone. The results from these two large multicenter clinical trials have led the medical community to re-evaluate how one should approach and treat patients with CAD and stable ischemic symptoms. In this special issue, experts from several disciplines discuss how the COURAGE and BARI 2D results have affected clinical practice and highlight the key questions that remain unanswered.
Introduction
The principal goals of myocardial revascularization in patients with coronary artery disease (CAD) are to decrease mortality and myocardial infarction (MI) and to improve angina and quality of life. Compared with medical therapy, percutaneous coronary intervention (PCI) has been associated with lower mortality or MI rates in patients with ST-segment elevation MI and in high-risk patients with acute coronary syndromes, and coronary artery bypass graft (CABG) surgery has been associated with lower mortality or MI rates in patients with left mainstem coronary disease and in those with multivessel coronary disease and impaired left ventricular systolic function. In contrast, the effectiveness of coronary revascularization for relieving angina has been widely recognized in both patients with acute coronary syndromes and stable ischemic heart disease, yet its benefit in reducing subsequent mortality and MI risk has not been shown in patients with stable CAD. Indeed, among 11 randomized clinical trials comparing PCI with medical therapy published between 1992 and 2005, involving fewer than 3000 patients, no differences in death, MI, or need for subsequent revascularization were demonstrable among groups, although almost all studies were underpowered for 'hard' clinical outcomes [1] .
In 2007, the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial established that for patients with stable CAD, an initial management strategy of PCI and optimal medical therapy did not reduce the long-term rates of death, MI, or other cardiovascular events as compared with optimal medical therapy alone [2] . The investigators prespecified eight subgroups, including age, sex, previous MI, diabetes, extent and severity of angiographic CAD, and ejection fraction less than 50%, but there was no significant interaction between treatment and any subgroup variable. These results garnered wide attention from practicing physicians, clinical researchers, and health policy decisionmakers. Two years later, the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial reported that a strategy of prompt coronary revascularization and intensive medical therapy did not reduce allcause mortality or the composite of death, MI or stroke compared with intensive medical therapy alone; however, in the group of patients appropriate for CABG surgery, prompt revascularization with CABG resulted in significantly lower rates of major cardiovascular events, specifically MI, than intensive medical therapy alone [3] . This trial focused on patients with type 2 diabetes mellitus in whom outcomes for any treatment for CAD are worse compared with those without diabetes. The BARI 2D trial showed that insulin sensitization and insulin provision glycemic treatment strategies, both with a target HbA1c less than 7%, yielded similar outcomes over 5 years of follow-up, and there was a suggestion that insulin sensitization therapy might be advantageous among patients undergoing revascularization. The evidence from these two large multicenter clinical trials has led the medical community to reevaluate the way we approach and treat patients with CAD and stable ischemic symptoms. In this special issue, experts from several disciplines discuss how the COURAGE and BARI 2D results have affected the clinical practice and highlight the key questions that remain unanswered.
Evaluation of patients with suspected coronary artery disease
Dr Menees and Dr Bates (pp. 386-390) carefully review the current guidelines on patient diagnosis, the clinical factors that are critical for risk stratification, and the process of selecting an appropriate treatment strategy. Using the American College of Cardiology/American Heart Association (ACC/AHA) recommendations for evaluating chest pain in patients with stable coronary disease, chest pain history, risk factor status, and noninvasive stress test results are used to classify patients. This information allows the physician to determine what additional tests should be ordered, to administer medical therapy at an appropriate level, and, possibly, to refer patients for coronary angiography.
The COURAGE and BARI 2D trials evaluated the benefit of immediate revascularization beyond optimal medical therapy for patients who had gone through a diagnostic and prognostic evaluation. The trial participants were referred for coronary angiography and were deemed appropriate for treatment with either initial medical therapy or revascularization. A large proportion of patients referred for coronary angiography in practice are similar to those in the COURAGE and BARI 2D trials with clinical comorbidities, significant inducible ischemia, and multivessel coronary disease. However, on the basis of the risk stratification scheme described in this paper, patients with the highest risk (e.g. left main disease) were excluded from these trials and referred for revascularization, and those with the lowest risk profile were excluded and referred for medical therapy. Consequently, the results from the COURAGE and BARI 2D trials do not change the standard of care for diagnosing CAD, as in both studies, coronary anatomy was defined by trial design and was a potential factor in defining which patients were included or excluded from enrollment. Information from future studies is needed to further refine the diagnostic process and to determine whether all such patients require diagnostic coronary angiography or whether noninvasive testing alone is useful for risk-stratifying patients and for defining when revascularization is warranted.
Clinical implications of BARI 2D and COURAGE trials on optimal medical therapy for coronary artery disease
Dr Lewis Kuller (pp. 391-396) summarizes what we have learned from the COURAGE and BARI 2D trials about medical therapy in patients with CAD and poses provocative questions to ponder. The COURAGE and BARI 2D trials provide confirmation that lipid lowering therapy and antihypertensive therapy are tremendously beneficial for patients with CAD. These studies do not resolve whether there are advantages associated with the lowering of HbA1c to below 7% or with the use of specific diabetes drug classes. As myocardial ischemia is present in many asymptomatic patients with type 2 diabetes, the evidence that intensive medical therapy slows the progression of atherosclerosis signifies that we should consider shifting the treatment objective in these patients from the prevention of microvascular disease to include the prevention of macrovascular disease. Dr Kuller suggests that imaging for atherosclerosis and atherosclerotic plaque might be used to predict MI or sudden death and that tools besides the current inflammatory measures such as C-reactive protein are needed to identify a hypercoagualable state, or to better identify the soft, inflamed atherosclerotic plaques that are vulnerable to acute rupture, fissure, or erosion. Furthermore, we need new drugs to reduce the risk of arterial thrombosis without increasing bleeding as a side effect. He concludes that COURAGE and BARI 2D trials prove that intensive medical therapy is feasible and effective in clinical trials, but it is difficult to translate this to community practice because preventive health care is underemphasized in the current health system. The existing 'fee for service' or 'pay for performance' reimbursement models that characterize existing healthcare policy do not reward physicians economically for achieving prevention goals and treatment targets. We should focus our attention on preventive care including exercise and smoking cessation to improve the health of patients.
The evolving role of percutaneous coronary intervention
Dr Holper and Dr Addo (pp. 397-401) define the patient population, the clinical circumstances, and the aspects of PCI that make it a critical component for managing CAD. In the COURAGE and BARI 2D trials, patients in low-tomoderate risk categories and stable symptoms derived no reduction of cardiovascular events with the addition of PCI. Yet, it is important for clinicians to recognize that patients assigned to an initial strategy of optimal medical care had the availability and the benefit of subsequent revascularization if clinically indicated. The medical groups in these trials did well because they could have a procedure when needed. The authors recommend that PCI should be used for markedly limiting symptoms or unstable symptoms that require urgent intervention. They emphasize that the ease, safety, and efficiency of PCI at the time of angiography make it an attractive tool, and the convenience continues to improve with advances like the use of radial arteries for access. PCI relieves symptoms, enhances patient quality of life, and reduces subsequent clinic visits for angina. Current PCI techniques allow the cardiologist to take on more complicated cases like total occlusions, diffuse lesions, and small vessels. The primary lesson from the COURAGE and BARI 2D trials is that optimal medical therapy should be provided to all patients with CAD as the foundation upon which all other treatments are configured, and for many patients, revascularization can be deferred until symptoms or the anatomy dictate. In contrast, these trials also illustrate the importance of carefully following coronary patients who are being treated with medical therapy and that PCI plays a key role under many circumstances.
Coronary artery bypass graft surgery for patients with diabetes and multivessel coronary artery disease: identifying patients who would benefit with coronary artery bypass graft and understanding the potential mechanisms involved Dr Greason and Dr Schaff (pp. 402-406) present a thorough review of the studies that have compared CABG with medical therapy and CABG with PCI for treating patients with CAD. The BARI 2D trial provides evidence that patients with type 2 diabetes and moderate CAD can be treated safely with medical therapy, but with careful follow-up and subsequent revascularization if needed. However, if ischemic symptoms persist or if severe multivessel disease is present, CABG has been shown to be the most effective treatment in terms of MI, cardiac death, and the need for repeat procedures. Indeed, the BARI 2D trial showed that CABG (but not PCI) patients had significantly fewer major cardiac events driven mainly by a reduction in MI than patients assigned to medical therapy. This is an important and novel finding not shown earlier in clinical trials and may be due to the higher risk patients selected for CABG. The authors propose that outcomes will continue to improve in this high-risk group of patients with recent advances in surgical techniques and the development of antiplatelet therapies. The BARI 2D data suggest that the combination of insulin sensitization and revascularization may provide further benefits for reducing the risk of MI. The results from this trial indicate that anatomic risk stratification may be useful for identifying high-risk patients with extensive anatomic CAD who would benefit from CABG. However, there is considerable controversy in the literature about screening patients with diabetes for coronary disease as the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study has shown that screening asymptomatic patients has a very low yield [4] . Therefore, the challenge is to determine how to best identify patients with severe anatomical coronary disease so that they can be referred for CABG.
Summary
The COURAGE and BARI 2D trial results have important implications for the way cardiologists approach clinical decision-making and practice. Evaluation of symptoms, risk factors, and test results are first used to risk stratify patients. In patients with stable or no symptoms with documented ischemia, the results from the COUR-AGE and BARI 2D trials provide a rationale for intensive medical therapy and lifestyle intervention, and a strong justification for delaying revascularization in patients with the characteristics of those enrolled in the trials. Intensive medical therapy aimed at treating dyslipidemia, hypertension, and glycemia must be available for all patients. Achieving and maintaining optimal treatment targets are essential to lower the risk for subsequent events. Preventive care that facilitates a healthy lifestyle should also be routine. These studies indicate that PCI is vital when symptoms become unstable and may be useful to relieve burdensome symptoms in other situations. The BARI 2D trial provides important new evidence that CABG is preferred over medical therapy alone for patients with diabetes and severe coronary disease, not only for symptom relief but also for reducing the rate of MI. Practitioners must carefully consider generalization of trial results to individual patients. In the case of CABG and BARI 2D risk stratification, knowledge of the patient's coronary anatomy is essential before applying the results to individual patients. In patients who are appropriate candidates for revascularization, a thoughtful and transparent discussion between the cardiologist, surgeon, and patient should be undertaken to ensure that the goals of therapy are aligned with the scientific evidence that supports it, and that the decision to proceed with PCI or CABG is individualized in the interests of what is best for the patient.
